Setup and daily tests are quick and easy for patients;
you control how alerts are managed6
The patient uses a mouse to click where a bump or wave in the dotted line appeared on the screen
ForeseeHome uses PHP to detect tiny changes in the central visual field, including metamorphopsia and scotoma
The patient’s daily test results are automatically sent to Notal Vision
Timely alerts can lead to earlier treatment6
Sample Monthly Report
You are alerted when a significant change from baseline occurs, which may indicate AMD progression
Monthly reports are emailed to your practice. Testing results are available 24/7 via the Notal Vision portal
You customize how alerts are shared; they can be sent to you or anyone in your office via email
In the study, 21% of patients experienced alerts from significant changes in (central and/or paracentral) metamorphopsia that did not result in a diagnosis of wet AMD
ForeseeHome measures statistically significant changes in metamorphopsia. Alerts that do not lead to a wet AMD diagnosis may still indicate other significant changes in the disease status that need to be addressed clinically
What the patient can expect
During the ForeseeHome test, a series of dotted lines flash on the screen and disappear
Using a mouse, the patient clicks where he/she saw a distortion (such as a bump or wave) on the dotted line
The test takes about 3 minutes per eye
Once the test is complete, data is automatically transmitted to the Notal Vision Data Monitoring Center
The patient uses a mouse to click where a bump or wave in the dotted
line has appeared on the screen.
The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration, as an aid in monitoring progression of disease factors causing metamorphopsia including but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.
The ForeseeHome AMD Monitoring Program is only available by physician order and is intended to be used as an addition to regular eye exams.
The technical component of the ForeseeHome AMD Monitoring Program is covered by Medicare, subject to its coverage requirements for the test, to assess patients with dry AMD who are at risk of developing wet AMD. Please refer to your local Medicare Administrative Contractor (MAC) for which the ordering physician resides concerning coverage availability for the physician professional services component of the test.